GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Cash Flow from Others

Abbisko Cayman (HKSE:02256) Cash Flow from Others : HK$-63.84 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Cash Flow from Others?

Abbisko Cayman's cash flow from others for the six months ended in Dec. 2023 was HK$-49.78 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-63.84 Mil.


Abbisko Cayman Cash Flow from Others Historical Data

The historical data trend for Abbisko Cayman's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Cash Flow from Others Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
44.45 662.37 1,874.51 9.93 -63.84

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Others Get a 7-Day Free Trial 1,539.26 14.38 -3.79 -14.06 -49.78

Abbisko Cayman Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-63.84 Mil.

Abbisko Cayman Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman (HKSE:02256) Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (HKSE:02256) Headlines

No Headlines